Want to see RGNX full AI Analyst Report?
RGNX Stock Chart & Stats
$9.73
-$0.02(-0.21%)
At close: 4:00 PM EDT
$9.73
-$0.02(-0.21%)
Day’s Range― - ―
52-Week Range$5.46 - $16.19
Previous CloseN/A
Volume1.25M
Average Volume (3M)2.66M
Market Cap
$793.48M
Enterprise Value$779.85
Total Cash (Recent Filing)$105.52M
Total Debt (Recent Filing)$68.95M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Nov 11, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.79
Shares Outstanding66,013,190
10 Day Avg. Volume2,223,240
30 Day Avg. Volume2,659,780
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.75Price Target Upside164.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.93
Revenue Forecast (FY)$191.53M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe pivotal result and strong biomarker-function relationship support RGX-202’s potential clinical value and regulatory case. If confirmed with larger follow-up, this could underpin approval, commercial adoption and meaningful future product revenue.
Pipeline And PartneringThe AbbVie collaboration provides external validation and non-dilutive milestone support, while multiple late-stage programs diversify the pipeline. Successful execution could create several commercialization paths rather than reliance on one candidate.
Improving Revenue MomentumRevenue growth indicates increasing contribution from collaborations, milestones or partnered programs. Although timing can be uneven, a larger revenue base improves operating leverage and may reduce dependence on repeated financing if pipeline progress continues.
Bears Say
Persistent Cash BurnContinued cash consumption means the company has not yet demonstrated self-funding economics. Additional clinical and commercial investment could require further equity or debt, creating dilution or financing risk before products generate durable revenue.
High Leverage And Eroded EquityElevated leverage and a reduced equity base limit financial flexibility for a clinical-stage company. Weak returns on capital and accumulated losses increase vulnerability if approvals, milestones or partnering proceeds arrive later than expected.
Regulatory And Evidence RiskA requirement for randomized evidence could materially delay RGX-202 approval and extend cash needs. The limited mature functional dataset and unresolved durability questions also leave uncertainty about whether early biomarker results will translate into lasting benefit.
RegenXBio News
RGNX FAQ
What was RegenXBio Inc.’s price range in the past 12 months?
RegenXBio Inc. lowest stock price was $5.46 and its highest was $16.19 in the past 12 months.
What is RegenXBio Inc.’s market cap?
RegenXBio Inc.’s market cap is $793.48M.
When is RegenXBio Inc.’s upcoming earnings report date?
RegenXBio Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were RegenXBio Inc.’s earnings last quarter?
RegenXBio Inc. released its earnings results on Aug 06, 2026. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.079 by $0.351.
Is RegenXBio Inc. overvalued?
According to Wall Street analysts RegenXBio Inc.’s price is currently Undervalued.
Does RegenXBio Inc. pay dividends?
RegenXBio Inc. does not currently pay dividends.
What is RegenXBio Inc.’s EPS estimate?
RegenXBio Inc.’s EPS estimate is -1.21.
How many shares outstanding does RegenXBio Inc. have?
RegenXBio Inc. has 66,013,190 shares outstanding.
What happened to RegenXBio Inc.’s price movement after its last earnings report?
RegenXBio Inc. reported an EPS of $0.43 in its last earnings report, beating expectations of $0.079. Following the earnings report the stock price went up 7.429%.
Which hedge fund is a major shareholder of RegenXBio Inc.?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.75 (164.65% Upside)
$25.75 (164.65% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 329.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.46%
Trailing 12-Months
Company Description
RegenXBio Inc.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RGNX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$25.75
▲(164.65% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
6.93% Insiders
13.64% Mutual Funds
11.73% Other Institutional Investors
54.41% Public Companies and
Individual Investors